Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NeuBase Therapeutics, Inc.    NBSE

NEUBASE THERAPEUTICS, INC.

(NBSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 7.25 support.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 7.14 USD
Weaknesses

No significant weakness

Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
NEUBASE THERAPEUTICS, INC.16.67%194
-
LONZA GROUP AG62.63%47 039
SEAGEN INC.71.39%34 074
IQVIA HOLDINGS INC.4.96%31 092
CELLTRION, INC.32.04%28 087
MODERNA, INC.259.10%27 716
IMMUNOMEDICS, INC.315.22%20 324
INCYTE CORPORATION3.57%19 779
ALNYLAM PHARMACEUTICALS, IN..11.72%14 922
HANGZHOU TIGERMED CONSULTIN..92.97%14 786
PHARMARON BEIJING CO., LTD.121.25%12 383
PPD, INC.0.00%11 915
CHARLES RIVER LABORATORIES ..50.68%11 435
QIAGEN N.V.45.74%11 268
BIO-TECHNE CORPORATION20.52%10 200
ICON PUBLIC LIMITED COMPANY11.47%10 132
More Results
Financials (USD)
Sales 2020 - - -
Net income 2020 -17,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -9,44x
Yield 2020 -
Capitalization 194 M 194 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 15
Free-Float 78,0%
Upcoming event on NEUBASE THERAPEUTICS, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality -
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision -
1 year Revenue revision -
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes